ROS1 and non-small cell lung carcinoma: We identified 1044 patients with ECOG PS of 0–2 who were treated with first-line pembrolizumab monotherapy for advanced NSCLC with PD-L1 expression ≥ 50% and no recorded EGFR/ALK/ROS1 genomic alteration, including 807 patients (77%) with ECOG PS of 0–1 and 237 (23%) with ECOG PS of 2 (Figure 1).